As part of Abcore’s antibody discovery platform, once a library is built and we have enriched the phage for the target, we need to screen individual clones to confirm binding of the nanobodies to the target. Abcore has a special way to do this. Traditionally this is done with the nanobodies bound to the phage, but we have a method of screening the nanobodies in the absence of phage. This allows us to directly detect nanobodies that bind the target, without having to worry about non-specific phage binding. This also avoids the attrition rate experienced when tests for non-specific phage is done. We call this OPIS (Off-Phage Initial Screen).
We can perform screening with almost all targets that we immunize with:
- MAP peptides
- Small molecules
- Live cells
We are proud to offer screening on live cells, which in conjunction with live cell panning allows us to accelerate nanobody discovery by getting the most physiologically relevant binders from the beginning of an antibody or nanobody discovery project.